Related Experiment Video
Updated: Aug 5, 2026
09:14
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy
J Cody Herron1, Kathryn G Link1, Natalie Meacham1
1Pfizer Inc., Translational Clinical Sciences, Cambridge, Massachusetts, USA.
CPT: Pharmacometrics & Systems Pharmacology
|August 1, 2026
Summary
Quantitative systems pharmacology models predict respiratory syncytial virus (RSV) antiviral efficacy. A 5-7 day treatment window post-symptom onset shows promise for pediatric RSV patients in clinical trials.
Area of Science:
- Pharmacology
- Virology
- Computational Biology
Background:
- Respiratory syncytial virus (RSV) infection causes significant morbidity, with limited treatment options for adults and children.
- Existing RSV antiviral candidates have shown efficacy in challenge studies but failed in patient trials, highlighting a critical unmet medical need.
- Understanding the transition of antiviral efficacy from preclinical to clinical settings is crucial for developing effective RSV therapies.
Purpose of the Study:
- To employ quantitative systems pharmacology (QSP) to model RSV infection and predict the efficacy of direct-acting antiviral agents.
- To develop virtual populations simulating viral load dynamics in healthy adults and pediatric patients.
- To identify optimal treatment parameters for potential success in Phase 3 RSV antiviral drug trials.
Main Methods:
- Developed a QSP model to represent RSV pathophysiology and antiviral effects.
- Created virtual populations for healthy adult challenge studies, incorporating sisunatovir (F-protein inhibitor) and zelicapavir (N-protein inhibitor).
- Developed a separate pediatric virtual population to align with Phase 2 zelicapavir study results.
Main Results:
- The QSP model successfully captured viral load dynamics in virtual challenge studies.
- Simulations indicated that a treatment window of 5 to 7 days post-symptom onset is feasible for observing virological efficacy in pediatric patients.
- Achieving >1× free EC90 at Cmin is projected as a key metric for therapeutic success.
Conclusions:
- QSP modeling provides a valuable framework for predicting RSV antiviral efficacy across different populations.
- The identified 5-7 day treatment window suggests a potential strategy for future pediatric RSV clinical trials.
- This approach can guide the development of effective RSV antiviral therapies for both children and adults, addressing a significant public health challenge.
Keywords:
antiviral therapyquantitative systems pharmacologyrespiratory syncytial virusviral dynamics modelingvirtual populationsMore Related Videos
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...